Jeffrey Houin, MD
Dermatology · Tupelo, MSNPI 1972537355
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $19,481 of the $26,779 with a category attached, or 72.7%. 37 manufacturers reported payments, led by Pfizer at 26.5% of the total. Reporting peaked in 2019 at $8,991 and has fallen 62.0% since, to $3,415 in 2025.
Across 1,115 payments — averaging $24.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$7K
- AbbVie$5K
- Novartis$2K
- Johnson & Johnson$2K
- Sun Pharmaceutical Industries Inc.$2K
- UCB, Inc.$1K
- plus $6K from 31 others
What the payments were for
- Speaking & faculty fees$6,55024%
- Food & beverage$19,48173%
- Education$7483%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 49 | $7,086 |
| AbbVie | 284 | $5,311 |
| Novartis | 162 | $2,446 |
| Johnson & Johnson | 142 | $2,306 |
| Sun Pharmaceutical Industries Inc. | 89 | $2,042 |
| UCB, Inc. | 63 | $1,156 |
| Regeneron Healthcare Solutions, Inc. | 44 | $962 |
| Lilly USA, LLC | 50 | $913 |
| Sanofi | 41 | $885 |
| LEO Pharma Inc. | 41 | $694 |
| E.r. Squibb & Sons, L.L.C. | 37 | $654 |
| Amgen | 17 | $365 |
| Merz North America, Inc. | 1 | $237 |
| Organon | 11 | $170 |
| Galderma Laboratories, L.p. | 10 | $162 |
| Dermavant Sciences, Inc. | 4 | $155 |
| Boehringer Ingelheim | 9 | $154 |
| Kerecis Limited | 6 | $133 |
| Mallinckrodt Hospital Products Inc. | 6 | $122 |
| Organogenesis Inc. | 5 | $112 |
| Incyte Corporation | 6 | $99 |
| Prugen, Inc. Pharmaceuticals | 8 | $91 |
| Genentech USA, Inc. | 5 | $77 |
| Mayne Pharma Commercial LLC | 3 | $71 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $58 |
| Dermira, Inc. | 2 | $40 |
| Biofrontera Inc. | 2 | $40 |
| Fresenius Kabi USA, LLC | 2 | $40 |
| DUSA Pharmaceuticals, Inc. | 2 | $32 |
| Melinta Therapeutics, LLC | 2 | $31 |
| Arcutis Biotherapeutics, Inc. | 2 | $31 |
| Smith+Nephew | 1 | $22 |
| Misonix Inc | 1 | $21 |
| Nabriva Therapeutics, PLC | 1 | $18 |
| Braeburn Inc. | 1 | $18 |
| Sandoz | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,779 in reported general payments places this provider in the 85th percentile of 78 dermatology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 188 | $733,300 |
| Skyrizi PenRisankizumab-Rzaa | 31 | $664,513 |
| StelaraUstekinumab | 25 | $480,461 |
| Humira(Cf) PenAdalimumab | 37 | $356,093 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 42 | $354,848 |
| TremfyaGuselkumab | 21 | $288,898 |
| RinvoqUpadacitinib | 22 | $139,511 |
| Humira PenAdalimumab | 20 | $125,222 |
| Enbrel SureclickEtanercept | 13 | $93,530 |
| AdbryTralokinumab-Ldrm | 12 | $42,296 |
| Dupixent SyringeDupilumab | 11 | $41,163 |
| Clobetasol Propionate | 326 | $19,694 |
| ZoryveRoflumilast | 13 | $11,054 |
| Tacrolimus | 84 | $8,608 |
| Triamcinolone Acetonide | 354 | $5,378 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara, Tremfya | $2,306 | $769,35846 claims |
| AbbVieRinvoq | $5,311 | $139,51122 claims |
| LEO Pharma Inc.Adbry | $694 | $42,29612 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $31 | $11,05413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 78 dermatology providers in Mississippi.
Other dermatology in Tupelo
- Bradley GreenhawTupelo$17K
- James ParkerTupelo$2K
- John BurkTupelo$2K
- Jeremy JacksonJackson$450K
- Lindsey ZubritskyOcean Springs$349K
- Maureen OffiahHattiesburg$275K
- Lyndsay ShippOxford$246K
- Steven ShapiroHattiesburg$165K
- Joseph TerracinaGreenville$86K
- Thy HuynhJackson$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.